Eli Lilly Initiates Phase III Clinical Trial of Muvalaplin to Reduce MACE Risk in Patients with Elevated Lipoprotein(a)

Data from the Drug Clinical Trial Registration and Information Disclosure Platform shows that a Phase III, randomized, double-blind, placebo-controlled study - MOVE - Lp(a) evaluating the effect of Muvalaplin on major adverse cardiovascular events in adults with elevated lipoprotein(a) levels who have experienced atherosclerotic cardiovascular events or are at increased risk for a first atherosclerotic cardiovascular event, conducted by Eli Lilly and Company, Lilly Suzhou Pharmaceutical Co., Ltd., and Lilly del Caribe, Inc., has been initiated. The clinical trial registration number is CTR20253466, and the initial information disclosure date was September 1, 2025.

The drug formulation is tablets, administered orally, once daily, with one tablet taken orally. The primary objective of this trial is to evaluate the effect of Muvalaplin on major adverse cardiovascular events in adult participants with elevated Lp(a) levels who have experienced an ASCVD event or are at increased risk of a first ASCVD event.

Muvalaplin Tablets are a chemical drug indicated for reducing the risk of MACE in patients with elevated Lp(a) levels who have confirmed CVD or an increased risk of a first CVE. Elevated Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease, and MACE includes cardiovascular death, myocardial infarction, etc., which can be diagnosed by testing Lp(a) levels and evaluating cardiovascular history.

The primary endpoint of this trial includes evaluating whether Muvalaplin is superior to placebo in reducing the risk of the MACE-4 composite endpoint; secondary endpoints include evaluating whether Muvalaplin is superior to placebo in reducing Lp(a) levels; evaluating whether Muvalaplin is superior to placebo in reducing the risks of the MACE-3 composite endpoint, modified MACE-3 composite endpoint, coronary MACE-3 composite endpoint, and MACE-3 + MALE composite endpoint.

Currently, the trial status is ongoing (not yet recruiting), with a target enrollment of 650 people in China and 10,450 people internationally.

Risk Warning: The market has risks, and investments should be made with caution. This article is automatically published by an AI large model based on a third-party database. Any information appearing in this article (including but not limited to individual stocks, comments, forecasts, charts, indicators, theories, or any form of expression, etc.) is for reference only and does not constitute personal investment advice. Due to issues such as the quality of the third-party database, we are unable to verify or confirm the authenticity and completeness of the data. Therefore, the content of this article may contain inaccuracies, incompleteness, or misleading information. Please refer to the company's official announcements for specific details. If you have any questions, please contact biz@staff.sina.com.cn.

Editorial Responsibility: Xiaolang Express